ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

109
Analysis
Health CareChina
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Refresh
18 Mar 2020 12:02

Trade Idea: Short Henlius Upon Lock-Up Expiry & 2H Results, HLX01 Likely Underperformed

Shanghai Henlius Biotech (2696 HK) IPO lock-up will expire on 25th of March, six months post its listing. The stock has been underwater since...

Logo
348 Views
Share
13 Mar 2020 14:16

InnoCare (诺诚健华) IPO: Bifurcated Book, Update of Our View

InnoCare launched the book building on March 11th to raise up to USD 288 million to list in Hong Kong. Book building will end on March 16...

Logo
439 Views
Share
bullishAlphamab Co Ltd
03 Dec 2019 01:53

Alphamab Oncology IPO: Valuation Easy to Swallow

Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
524 Views
Share
25 Sep 2019 08:13

Henlius (复宏汉霖) Post-IPO Trading: Weak Demands Ahead of Debut, Downside Remains

Shanghai Henlius' IPO was priced at the low end and started trading today. We have highlighted in our earlier note that the IPO is over-valued with...

Logo
493 Views
Share
18 Sep 2019 15:37

Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China

We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...

Logo
518 Views
Share
x